Travere Therapeutics, Inc. TVTX

Latest FY: 2025 Healthcare Biotechnology
Market Price $66.50
Market Cap $6.18B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑110.5% YoY
$490.73M
3-Yr CAGR: 32.3%
Net Income ↑92.1% YoY
-$25.55M
Net Margin: -5.2%
Free Cash Flow ↑94.0% YoY
-$20.37M
FCF Yield: -0.33%
EPS (Diluted) ↑92.9% YoY
$-0.29
Basic: $-0.29
Return on Equity Efficiency
-22.2%
ROA: -4.2%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (TVTX)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $133.6M $129.0M $-47.9M $-1.29 0.00% $-3.4M $-4.9M
FY 2017 $154.9M +16.0% $151.3M $-59.7M -24.7% $-1.54 -19.4% 0.00% $7.4M $6.5M +233.8%
FY 2018 $164.2M +6.0% $154.4M $-102.7M -71.9% $-2.54 -64.9% 0.00% $-25.0M $-25.7M -494.2%
FY 2019 $175.3M +6.8% $156.5M $-146.4M -42.6% $-3.46 -36.2% 0.00% $-58.2M $-58.4M -127.4%
FY 2020 $198.3M +13.1% $179.3M $-169.4M -15.7% $-3.56 -2.9% 0.00% $-42.7M $-49.5M +15.2%
FY 2021 $227.5M +14.7% $207.4M $-180.1M -6.3% $-3.01 +15.4% 0.00% $-14.8M $-19.9M +59.8%
FY 2022 $212.0M -6.8% $200.7M $-278.5M -54.6% $-4.37 -45.2% 0.00% $-186.3M $-186.5M -837.4%
FY 2023 $145.2M -31.5% $133.8M $-111.4M +60.0% $-1.50 +65.7% 0.00% $-280.0M $-280.7M -50.5%
FY 2024 $233.2M +60.5% $222.0M $-321.5M -188.6% $-4.08 -172.0% 0.00% $-237.5M $-338.7M -20.7%
FY 2025 $490.7M +110.5% $480.0M $-25.5M +92.1% $-0.29 +92.9% 0.00% $37.8M $-20.4M +94.0%
$

Valuation

Market Price $66.50
Market Cap $6.18B
Enterprise Value $6.09B
P/E Ratio N/A
P/B Ratio 53.86
FCF Yield -0.33%
Dividend Yield N/A
Shares Outstanding 92,992,900
%

Profitability & Margins

Gross Margin 97.81%
Operating Margin -12.80%
Net Margin -5.21%
Return on Equity (ROE) -22.25%
Return on Assets (ROA) -4.22%
Asset Turnover 0.81x
Revenue 3-Yr CAGR 32.28%
🛡️

Financial Health & Liquidity

Current Ratio 2.74
Cash Ratio 0.58
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $93.03M
Total Debt N/A
Book Value / Share $1.23
💧

Cash Flow Efficiency

Operating Cash Flow $37.78M
Capital Expenditures (CapEx) $58.16M
Free Cash Flow -$20.37M
OCF / Revenue 7.70%
FCF / Revenue -4.15%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.29
EPS (Basic) $-0.29
Dividends / Share N/A
Book Value / Share $1.23
EPS YoY Growth 92.89%
🏛️

Balance Sheet (FY 2025)

Total Assets $605.19M
Total Liabilities $490.36M
Stockholders' Equity $114.83M
Current Assets $437.56M
Current Liabilities $159.90M